A New Route for the Preparation of Substituted 2,2-Difluorostyrenes and a Convenient Route to Substituted (2,2,2-Trifluoroethyl)benzenes
摘要:
The (2,2-difluoroethenyl)zinc reagent II is coupled with aryl iodides or bromides in the presence of Pd(PPh3)(4) in DMF to give the corresponding 2,2-difluorostyrenes IV. The 4-substituted (tetrafluoroaryl)copper reagents are coupled with 2,2-difluoro-1-iodoethylene (I) to produce the corresponding styrene derivatives VII. Both methods provide good yields of the coupled products. These products react with wet KF in DMF or DMSO to form the (2,2,2-trifluoroethyl)benzene derivatives VIII in good yields.
作者:Haiwen Xiao、Zhonglin Liu、Haigen Shen、Benxiang Zhang、Lin Zhu、Chaozhong Li
DOI:10.1016/j.chempr.2019.02.006
日期:2019.4
Direct trifluoromethylation of C(sp3)–H bonds, especially in late stages, remains a formidable challenge. Herein, we describe the copper-catalyzed benzylicC(sp3)–H trifluoromethylation. With Cu(I) or Cu(II) as the catalyst, (bpy)Zn(CF3)2 (bpy = 2,2′-bipyridine) as the CF3 source, and NFSI (or Selectfluor) as the oxidant, site-selective benzylicC(sp3)–H trifluoromethylation is successfully implemented
[EN] DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS DIHYDROPYRAZOLOPYRIMIDINONE UTILISÉS EN TANT QU'EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2016192083A1
公开(公告)日:2016-12-08
The present invention is directed to dihydropyrazolopyrimidinonecompounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
[EN] PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLYLE PYRIMIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2016154081A1
公开(公告)日:2016-09-29
The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
Nickel‐Catalyzed Direct Trifluoroethylation of Aryl Iodides with 1,1,1‐Trifluoro‐2‐Iodoethane via Reductive Coupling
作者:Han Li、Jie Sheng、Guang‐Xu Liao、Bing‐Bing Wu、Hui‐Qi Ni、Yan Li、Xi‐Sheng Wang
DOI:10.1002/adsc.202000985
日期:2020.12.8
CF3CH2I has been developed, demonstrating high efficiency, excellent functional‐group compatibility, especially with large sterically hindered groups. The key to success is the combination of nickel with readily available nitrogen and phosphine ligands. The powerful potential of this strategy is further demonstrated by the late‐stage modification of several derived bioactive molecules.
Switchable 2,2,2-Trifluoroethylation and<i>gem</i>-Difluorovinylation of Organoboronic Acids with 2,2,2-Trifluorodiazoethane
作者:Guojiao Wu、Yifan Deng、Chaoqiang Wu、Xi Wang、Yan Zhang、Jianbo Wang
DOI:10.1002/ejoc.201402597
日期:2014.7
The transition-metal-free 2,2,2-trifluoroethylation and gem-difluorovinylation of arylboronic acids were developed. By employing different reaction conditions, these transformations provide both (2,2,2-trifluoroethyl)arenes and gem-difluorovinylarenes from arylboronic acids and 2,2,2-trifluorodiazoethane. The operation is simple and scalable with good functional group tolerance.